Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer

New England Journal of Medicine

Volumn 374, Issue 8, 2016, Pages 738-748

  Chan, J K ^a   Brady, M F ^b   Penson, R T ^c   Huang, H ^b   Birrer, M J ^c   Walker, J L ^d   DiSilvestro, P A ^e   Rubin, S C ^f   Martin, L P ^g   Davidson, S A ^h   Huh, W K ⁱ   O'Malley, D M ^j   Boente, M P ^k   Michael, H ^l   Monk, B J ^m  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e WOMEN AND INFANTS HOSPITAL   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k Minnesota Hematology Oncology   (United States)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MIDDLE AGED; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; QUALITY OF LIFE; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VENOUS THROMBOEMBOLISM; VOMITING; YOUNG ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; OVARIAN NEOPLASMS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 84959421414     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1505067     Document Type: Article

References (36)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
2. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
3. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96.
4. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45.
5. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302-8.
6. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996; 88: 1308-14.
7. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascular-ized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14: 31-6.
8. Griffon-Etienne G, Boucher Y, Brek-ken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-82.
9. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235-42.
10. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23: 5983-92.
11. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastu-zumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-9.
12. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
13. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense pa-clitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013; 14: 1020-6.
14. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014; 15: 396-405.
15. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;6 8:1331-7.
16. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol 2001; 19:1809-17.
17. Yost KJ, Eton DT. Combining distribution-and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 2005;28:172-91.
18. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
20. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19: 4054-7.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
22. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leuco-vorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
23. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 35 8: 16 63-71.
24. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gyne-col Oncol 2008;109:370-6.
25. Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006; 108: 521-8.
26. Fuh KC, Shin JY, Kapp DS, et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol 2015; 136: 491-7.
27. Hertz DL. Germline pharmacogenet-ics of paclitaxel for cancer treatment. Pharmacogenomics 2013;14:1065-84.
28. Bosó V, Herrero MJ, Santaballa A, et al. SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics 2014; 15: 1845-58.
29. Seidman AD, Conlin AK, Bach A, et al. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanopar-ticle albumin-bound paclitaxel with beva-cizumab as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 2013;13(4):239-246.e1.
30. Jain RK. An indirect way to tame cancer. Sci Am 2014; 310: 46-53.
31. Jain RK. Normalizing tumor vascula-ture with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
32. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppres-sive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 2012; 109: 17561-6.
33. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
34. Chan JK, Herzog TJ, Hu L, et al. Beva-cizumab in treatment of high-risk ovarian cancer-a cost-effectiveness analysis. Oncologist 2014;19:523-7.
35. Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29: 1247-51.
36. Dalton HJ, Yu X, Hu L, et al. An economic analysis of dose dense weekly pa-clitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecol Oncol 2012;124:199-204.